Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine

J Pediatr. 1996 Feb;128(2):275-8. doi: 10.1016/s0022-3476(96)70408-0.

Abstract

A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis. Corticosteroid administration was ineffective, whereas a prompt response to cyclosporine was observed. Two months later, Pneumocystis carinii pneumonia developed.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / therapeutic use
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Juvenile / drug therapy*
  • Bone Marrow / ultrastructure
  • Child
  • Cyclosporine / administration & dosage
  • Cyclosporine / therapeutic use*
  • Humans
  • Macrophage Activation / drug effects*
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use*
  • Phagocytes / ultrastructure
  • Pneumonia, Pneumocystis / drug therapy
  • Sulfamethoxazole / administration & dosage
  • Sulfamethoxazole / therapeutic use
  • Trimethoprim / administration & dosage
  • Trimethoprim / therapeutic use

Substances

  • Anti-Infective Agents
  • Antirheumatic Agents
  • Cyclosporine
  • Trimethoprim
  • Sulfamethoxazole
  • Methotrexate